Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Asset disposition
Inv. presentation
Acq. announced
|
|
OPKO HEALTH, INC. (OPK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/28/2021 |
GN
| OPKO Health Reports 2021 First Quarter Business Highlights and Financial Results |
| 02/03/2021 |
GN
| OPKO Health to Report Fourth Quarter 2020 Financial Results on February 18, 2021 |
| 01/13/2021 |
GN
| Sian Capital Urges OPKO Health to Address Apparently Misleading 4Q'20 Guidance |
| 01/05/2021 |
GN
| OPKO Health to Present at the 39th Annual J.P. Morgan Healthcare Conference |
| 12/21/2020 |
GN
| OPKO Health Appoints Dr. Roger Medel to its Board of Directors |
| 11/20/2020 |
GN
| Sian Capital Sends Letter to OPKO Health Regarding its Decision to Apparently Withhold Rayaldee From Many Patients Amidst COVID-19's Second Wave |
| 11/12/2020 |
GN
| Sian Capital Issues Open Letter to Stockholders of OPKO Health |
| 11/11/2020 |
GN
| OPKO Health to Participate in Three Upcoming Investment Conferences |
| 10/29/2020 |
GN
| Sian Capital Highlights Paths to Meaningful Value Creation at OPKO Health |
| 10/13/2020 |
GN
| OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020 |
| 09/15/2020 |
GN
| OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients |
| 09/02/2020 |
GN
| OPKO Health to Participate in Two September Investment Conferences |
| 08/05/2020 |
GN
| OPKO Health to Participate in BTIG Virtual Biotechnology Conference |
| 06/09/2020 |
GN
| OPKO Health Announces Positive Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Japanese Children with Growth Hormone Deficiency |
| 04/30/2020 |
GN
| OPKO Health to Report First Quarter 2020 Financial Results on May 6, 2020 |
| 04/22/2020 |
GN
| Somatrogon Phase 3 Pediatric Trial Results will be presented on June 8 at ENDO Online 2020 |
| 03/25/2020 |
GN
| OPKO Health Reports Interim Results for Two Ongoing RAYALDEE Studies |
| 03/10/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of OPKO Health, Inc. – OPK |
| 02/20/2020 |
GN
| OPKO Health to Report Fourth Quarter 2019 Financial Results on February 26, 2020 |
| 12/19/2019 |
GN
| BioReference Laboratories Showcases 2019 Growth through the Addition of Cutting Edge Tests, Greater Access to Services, and Optimized Patient Experience |
| 12/19/2019 |
GN
| OPKO Health to Present at the 38th Annual J.P. Morgan Healthcare Conference |
| 11/15/2019 |
GN
| Novitas Issues Final Local Coverage Determination for the 4Kscore® Test |
| 11/04/2019 |
GN
| BioReference Laboratories and GeneDx to Present at NSGC 2019, Demonstrating Commitment to Genetic Counselors and the Research of Rare Genetic Disorders |
| 10/24/2019 |
GN
| OPKO Health, Inc. Announces Pricing of its Offering of Common Stock |
| 10/21/2019 |
GN
| OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency |
| 08/29/2019 |
GN
| OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency |
| 07/01/2019 |
GN
| OPKO Health's BioReference Laboratories Forms a Strategic Collaboration With SOMOS to Improve Health Outcomes of Underserved New Yorkers |
| 07/01/2019 |
GN
| BioReference Laboratories Forms a Strategic Collaboration with SOMOS to Improve Health Outcomes of Underserved New Yorkers |
| 06/28/2019 |
GN
| Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test |
| 06/20/2019 |
GN
| OPKO Health Submits De Novo Request to the U.S. FDA for the 4Kscore® Test |
| 06/07/2019 |
GN
| BioReference Laboratories Supports Man Cave Health During National Men's Health Month |
| 05/17/2019 |
GN
| Aerobic Vaginitis (AV) Testing Now Available At BioReference Laboratories |
| 05/07/2019 |
GN
| OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results |
| 05/02/2019 |
GN
| BioReference Laboratories to Present at ACOG 2019, Demonstrating Commitment to the Research of Hereditary Conditions |
|
|
|